Market revenue in 2023 | USD 576.7 million |
Market revenue in 2030 | USD 898.6 million |
Growth rate | 6.5% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 54.5% in 2023. Horizon Databook has segmented the India inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The market penetration of biologics and biosimilars for the treatment of IBD is very less. According to data published by irjournal.org, almost 99% of IBD patients received amino salicylates, and around 42% received corticosteroids, whereas only 1.5% of total IBD patients received biologics as a therapy.
India has not advanced, and there is little-to-no awareness of these conditions at ground level. In addition, people are dependent on drugs for IBD that are manufactured outside the country. Therefore, there is a major opportunity for local manufacturers to develop new cost-effective treatments for IBD.
Government bodies increasingly providing information on symptoms, causes, diagnosis, and management of IBD is among the factors anticipated to boost the market. For instance, the Ministry of Health and Family Welfare (MoHFW) is single-point access that provides information about management of IBD.
Horizon Databook provides a detailed overview of country-level data and insights on the India inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into India inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account